Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00200395 · ClinicalTrials.gov registry record · Phase 2

OSI-774 (Erlotinib, Tarceva) in Elderly Patients

A Phase 2 study, sponsored by Montefiore Medical Center.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target

NCT00200395 is a Phase 2 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00200395, a Phase 2 study, has completed, sponsored by Montefiore Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target

Study Summary

The purpose of this research study is to determine if OSI-774 (Tarceva) is effective in the treatment of non-small cell lung cancer and to further study its side effects. The investigators would also like to estimate disease-related symptom improvement rates using a questionnaire.

Interventions

  • DRUG Tarceva

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2003-07-02
Est. Completion 2007-01-12
Phase Phase 2

Sponsor

Montefiore Medical Center

345 total trials

What the Registry Record Tells You About NCT00200395

The ClinicalTrials.gov registry entry for NCT00200395 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Tarceva is the first listed.

NCT00200395 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00200395 about?

NCT00200395 is a clinical study titled "OSI-774 (Erlotinib, Tarceva) in Elderly Patients". The purpose of this research study is to determine if OSI-774 (Tarceva) is effective in the treatment of non-small cell lung cancer and to further study its side effects. The investigators would also like to estimate disease-related symptom improvement rates using a questionnaire.

What is the current status of trial NCT00200395?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2003-07-02. Estimated completion is 2007-01-12.

What interventions are being tested in trial NCT00200395?

The interventions under investigation include: Tarceva (DRUG).

Who is sponsoring clinical trial NCT00200395?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.